Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Autism after high school: Making the transition

  • New technology shows promise for delivery of therapeutics to the brain

  • Higher suicide risk after served prison sentence

  • Major factor in development of Huntington's disease uncovered

  • Neglect of culture in medicine is 'single biggest barrier' to achieving better health

  • Different brain tumors have the same origin, new findings show

  • Politics can interact with evolution to shape human destiny

  • Heavy drinking in adolescence associated with lasting brain changes, animal study suggests

  • From age 8 to 80, expert reveals the price we pay for not sleeping

  • Evolution of competitiveness: Scientists explain diversity in competitiveness

  •